Current cancer treatments are more promising than ever. As a result, patients with cancer live longer and the number of cancer survivors have increased significantly. This is a trend that makes us hopeful. – Unfortunately however, many of the survivors are living with cancer-related neuropathic pain. This common condition can be caused by treatments like chemotherapy, radiotherapy or surgery – and it has a significantly negative impact on patients’ lives. That’s why Grünenthal is collaborating with partners from across the healthcare sector to conduct an online survey that aims to give patients with cancer-related neuropathy a voice.

The survey was designed by a multi-disciplinary team of representatives from patient organisations, as well as oncologists, pain specialists and nurses. It will gather insights from patients above 18 years of age who have a diagnosis of cancer-related neuropathic pain. The survey was launched on 10 February and will remain open to participants in 13 European countries until 18 April. The results will then be made available in May 2021. Key findings from the survey will form the basis for discussions among healthcare professionals and policymakers, with the aim of developing recommendations on how to improve the way cancer-related neuropathic pain is managed.

The survey takes around 15 minutes to complete. You can access it here: